JP2021526509A5 - - Google Patents

Info

Publication number
JP2021526509A5
JP2021526509A5 JP2020564389A JP2020564389A JP2021526509A5 JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5 JP 2020564389 A JP2020564389 A JP 2020564389A JP 2020564389 A JP2020564389 A JP 2020564389A JP 2021526509 A5 JP2021526509 A5 JP 2021526509A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
seq
sequence shown
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564389A
Other languages
English (en)
Japanese (ja)
Other versions
JP7294758B2 (ja
JP2021526509A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031983 external-priority patent/WO2019222082A1/en
Publication of JP2021526509A publication Critical patent/JP2021526509A/ja
Publication of JP2021526509A5 publication Critical patent/JP2021526509A5/ja
Priority to JP2023093016A priority Critical patent/JP7662707B2/ja
Application granted granted Critical
Publication of JP7294758B2 publication Critical patent/JP7294758B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564389A 2018-05-14 2019-05-13 抗cd24組成物及びその使用 Active JP7294758B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093016A JP7662707B2 (ja) 2018-05-14 2023-06-06 抗cd24組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671193P 2018-05-14 2018-05-14
US62/671,193 2018-05-14
PCT/US2019/031983 WO2019222082A1 (en) 2018-05-14 2019-05-13 Anti-cd24 compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093016A Division JP7662707B2 (ja) 2018-05-14 2023-06-06 抗cd24組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021526509A JP2021526509A (ja) 2021-10-07
JP2021526509A5 true JP2021526509A5 (cg-RX-API-DMAC7.html) 2022-05-19
JP7294758B2 JP7294758B2 (ja) 2023-06-20

Family

ID=68540727

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564389A Active JP7294758B2 (ja) 2018-05-14 2019-05-13 抗cd24組成物及びその使用
JP2023093016A Active JP7662707B2 (ja) 2018-05-14 2023-06-06 抗cd24組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023093016A Active JP7662707B2 (ja) 2018-05-14 2023-06-06 抗cd24組成物及びその使用

Country Status (13)

Country Link
US (3) US12286485B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813877A4 (cg-RX-API-DMAC7.html)
JP (2) JP7294758B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250122537A (cg-RX-API-DMAC7.html)
CN (2) CN116589582A (cg-RX-API-DMAC7.html)
AU (2) AU2019269361C1 (cg-RX-API-DMAC7.html)
EA (1) EA202092306A1 (cg-RX-API-DMAC7.html)
IL (1) IL278689B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020012091A (cg-RX-API-DMAC7.html)
SG (1) SG11202010589YA (cg-RX-API-DMAC7.html)
TW (1) TWI835794B (cg-RX-API-DMAC7.html)
WO (1) WO2019222082A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006647B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
JP2022538870A (ja) * 2019-06-25 2022-09-06 イチロフ テック リミテッド 抗cd24抗体及びその使用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR20230143177A (ko) * 2021-02-08 2023-10-11 안텐진 바이올로직스 리미티드 신규한 항-cd24 항체
WO2022178163A2 (en) * 2021-02-18 2022-08-25 Health Research, Inc. Antibody-derived t cell activating technologies
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023280042A1 (zh) * 2021-07-06 2023-01-12 盛禾(中国)生物制药有限公司 一种抗cd24抗体及其应用
CN118076625A (zh) * 2021-09-28 2024-05-24 广州昂科免疫生物技术有限公司 包含071核心肽的融合蛋白及其用途
CN113831412B (zh) * 2021-10-13 2023-06-20 宜明昂科生物医药技术(上海)股份有限公司 靶向cd24的抗体及其制备和用途
CN118369340A (zh) * 2021-11-25 2024-07-19 盛禾(中国)生物制药有限公司 一种双特异性抗原结合蛋白
AU2022404358A1 (en) * 2021-12-07 2024-07-04 Beijing Kanghong Biomedical Co., Ltd Anti-cd24 antibody and use thereof
AU2023258034A1 (en) * 2022-04-20 2024-11-07 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer
CN115947855B (zh) * 2022-05-20 2023-10-27 杭州邦顺制药有限公司 抗cd24抗体的制备及其用途
AU2023320486A1 (en) * 2022-08-04 2025-02-20 Memorial Hospital For Cancer And Allied Diseases Anti-cd24 antibodies and uses thereof
JP2025535498A (ja) * 2022-10-27 2025-10-24 ベイジン ネオエックス バイオテック リミテッド Cd24に対する抗体およびその使用
CN120112561A (zh) * 2022-11-01 2025-06-06 南京昂科免疫生物医药有限公司 一种cd24结合蛋白及其用途
CN115960243B (zh) * 2023-01-09 2025-05-06 中国药科大学 靶向cd24和cd3的双特异性抗体及其应用
CN121311506A (zh) * 2023-06-09 2026-01-09 天境生物科技(上海)有限公司 抗-cd24抗体及其用途
EP4790070A1 (en) * 2023-10-04 2026-08-12 Daegu Gyeongbuk Institute of Science and Technology Anti-cd24 antibody or antigen-binding fragment thereof, and use thereof
WO2025077809A1 (zh) * 2023-10-12 2025-04-17 江苏融泰生物技术有限公司 抗体融合蛋白及应用
WO2025085805A1 (en) * 2023-10-20 2025-04-24 OncoC4, Inc. Anti-cd24/anti-cd3 bispecific binding proteins and uses thereof
TW202535944A (zh) * 2023-11-08 2025-09-16 美商飛斯特醫療公司 Cd24抗體
WO2025151423A1 (en) * 2024-01-08 2025-07-17 OncoC4, Inc. Anti-cd24 antibody drug conjugates and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化n端ペプチドに対する抗体
CN1894413A (zh) 2003-03-26 2007-01-10 特鲁比昂药品公司 识别cd3或4-1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2009063461A1 (en) 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
EP2574627A1 (en) * 2011-09-30 2013-04-03 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Particular uses of CD24 inhibitors
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN103819561A (zh) 2014-01-22 2014-05-28 中国药科大学 抗cd24单克隆抗体、其可变区序列及其应用
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US9804170B2 (en) * 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
CN105505869A (zh) * 2015-12-21 2016-04-20 河南大学淮河医院 一种针对肿瘤干细胞的嵌合抗原受体t细胞
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1

Similar Documents

Publication Publication Date Title
CN112955471B (zh) Cd3抗体及其药物用途
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
DK1976880T3 (en) Pharmaceutical compositions with resistance to soluble cea
CN116261590B (zh) 抗cd3抗体以及其用途
US20240197931A1 (en) Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
CN118987201A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
WO2021254481A1 (zh) 抗Claudin18.2抗体以及其用途
JP2021510736A5 (cg-RX-API-DMAC7.html)
WO2020114479A1 (zh) 多特异性蛋白分子
US20210040213A1 (en) Immunomonotherapy for urothelial carcinoma
JP2025148435A (ja) ヒトがんの治療のためのモノクローナル抗体neo-201
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2025016452A (ja) 癌の治療における放射免疫療法と免疫チェックポイント療法との組み合わせ
Caracciolo et al. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
CA3249273A1 (en) CD28 Bispecific Antibodies for Targeted T Lymphocyte Activation
EP3092252A1 (en) ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
JP2019535753A (ja) 抗CD300f抗体およびその利用
KR20230028386A (ko) 인간 질환의 치료를 위한 cd38 항체
JP2022523360A5 (cg-RX-API-DMAC7.html)
JP2025510642A5 (cg-RX-API-DMAC7.html)
CN118557748A (zh) 使用抗cd123免疫缀合物的治疗方法
TW202005983A (zh) 抗-人類pd-l1之抗體及其用途
CA3099974A1 (en) Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
Clark et al. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment
Garambois et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers